6 February 2026·PIB

Revamped RPTUA Scheme

In this note

1. At a Glance

Revised Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) is a Central Sector grant-in-aid scheme by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers to help small/medium pharma units upgrade to Revised Schedule M and WHO-GMP standards [1][2].
Outlay ₹300.10 crore for FY 2024-25 to 2025-26; incentive 10–20% of investment, capped at ₹2 crore per unit [1][2].
Relevant for GS-III (Industry, Pharmaceuticals, Atmanirbhar Bharat) and GS-II (Health regulation, MSME welfare).

PIB release dated 06 February 2026 provided sanction status: grant-in-aid sanctioned to 255 pharmaceutical companies for ₹248.20 crore so far [1].
Closely tied to the Revised Schedule M compliance deadline of 31 December 2025 for MSME pharma manufacturers (<₹250 cr turnover) [3].

Originally launched as PTUAS in 2022 (under "Strengthening of Pharmaceuticals Industry — SPI" umbrella) for MSME pharma upgrades [2].
Revamped as RPTUAS in March 2024 by Department of Pharmaceuticals to align with the Revised Schedule M notification [1][2].
Schedule M revision: amended via G.S.R. 922(E) dated 28.12.2023; large units (>₹250 cr) deadline 28 June 2024; MSMEs (<₹250 cr) extended conditionally up to 31.12.2025 [3].
Sits alongside other DoP schemes: PLI for Pharma, PLI for Bulk Drugs, Bulk Drug Parks, PRIP (Promotion of Research & Innovation in Pharma-MedTech), APCF (Assistance to Pharma Industries for Common Facilities) [2].

Nodal Ministry/Dept: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [1].
Launch: March 2024 [1].
Outlay: ₹300.10 crore (FY 2024-25 & 2025-26) [1].
Eligibility: Existing pharma units with average turnover up to ₹500 crore over last 3 years [2].
Incentive Slabs (% of investment, max ₹2 crore) [1]:
Turnover ₹1–50 cr → 20%
Turnover ₹50–250 cr → 15%
Turnover ₹250–500 cr → 10%
Compliance Anchors: Revised Schedule M to the Drugs Rules, 1945 and WHO-GMP [1].
Disbursement Trigger: Certification by State/Central drug regulator of Schedule M + WHO-GMP compliance [1].
Sanctions to date: 255 units, ₹248.20 crore (incl. 5 units, ₹5.92 cr in Tamil Nadu) [1].

Economic: Targets the long tail of ~10,500 MSME pharma units; helps preserve India's "pharmacy of the world" status by averting closures due to Schedule M compliance costs [1][3].
Scientific/Technological: Pushes adoption of WHO-GMP norms — validated processes, pharmaceutical water systems, computerised storage, quality risk management — enabling export competitiveness [1].
Legal/Regulatory: Operationalises Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945; Schedule M revision via G.S.R. 922(E), 28.12.2023 is the underlying regulatory trigger [3].
Administrative/Federal: Implementation requires coordination between CDSCO (Centre) and State Drug Controllers for certification; State drug authorities issue compliance certificates that unlock the grant [1][3].
Social/MSME: Tiered incentive (20% for smallest units) protects micro/small manufacturers disproportionately burdened by capex requirements [1].

28 June 2024: Revised Schedule M came into force for large manufacturers (>₹250 cr) [3].
February 2025: Conditional extension granted to MSME pharma manufacturers till 31.12.2025 for Schedule M compliance, subject to submission of upgradation plan [3].
06 February 2026: PIB update — 255 units sanctioned, ₹248.20 cr disbursed under RPTUAS [1].

RPTUAS launched March 2024 by Department of Pharmaceuticals (not Ministry of Health) [1].
Outlay ₹300.10 crore over 2 financial years (2024-25 & 2025-26) [1].
Maximum assistance per unit: ₹2 crore [1].
Top slab: 20% incentive for units with turnover ₹1–50 crore [1].
Eligibility ceiling: turnover ₹500 crore [2].
Schedule M is part of Drugs Rules, 1945 (under Drugs & Cosmetics Act, 1940) [3].
Revised Schedule M notified via G.S.R. 922(E) dated 28.12.2023 [3].
MSME pharma Schedule M deadline extended to 31 December 2025 [3].
Grant release contingent on drug regulator certification of WHO-GMP + Schedule M compliance [1].
Parent ministry: Ministry of Chemicals and Fertilizers [1].
As of Feb 2026: 255 units, ₹248.20 cr sanctioned [1].
RPTUAS is the successor to PTUAS (under SPI umbrella) [2].

GS-III: Indian Economy — Industrial Policy, MSMEs; "Pharmacy of the World" agenda; effects of liberalisation on industry.
GS-II: Government policies/interventions in health sector; regulatory architecture (CDSCO).
Possible stems:
"India's MSME pharma sector faces a quality–cost trade-off in complying with Revised Schedule M. Examine the role of RPTUAS in resolving it."
"Discuss the institutional and regulatory framework for ensuring drug quality in India, with reference to recent reforms."
"Evaluate the Department of Pharmaceuticals' suite of schemes (PLI, RPTUAS, PRIP, Bulk Drug Parks) in advancing Atmanirbhar Bharat in pharma."

Revised Schedule M & Drugs and Cosmetics Act, 1940 — regulatory backbone of RPTUAS.
PLI Scheme for Pharmaceuticals & Bulk Drugs — complementary supply-side incentive.
PRIP Scheme — R&D push (₹11,000 cr) in Pharma-MedTech [2].
Bulk Drug Parks Scheme — infrastructure pillar of pharma self-reliance.
CDSCO & State Drug Controllers — the certifying authority chain.
Jan Aushadhi (PMBJP) — quality generics distribution; depends on GMP-compliant supply.
WHO Good Manufacturing Practices — global benchmark.
National Pharmaceutical Pricing Authority (NPPA) — price control complement.

Wrong ministry: RPTUAS is under Chemicals & Fertilizers / DoP, NOT Ministry of Health & Family Welfare.
Confusing RPTUAS (grant for upgradation) with PLI Pharma (incentive on incremental sales).
Misquoting outlay: it is ₹300.10 cr for 2 years, not annual.
Schedule M sits under Drugs Rules, 1945, not directly under the 1940 Act.
Assuming all pharma units are eligible — cap is ₹500 cr turnover; bigger firms excluded.